Joe Biden threatens cancer funding cuts if hospitals don't collaborate more
'I believe we can do in the next five years what would normally take 10 years'
Speaking at a cancer summit at Howard University in Washington, Biden made an impassioned plea for increased urgency in the fight against cancer. The event was part of a national day of action in the U.S. involving hundreds of researchers, patient advocates and data experts.
Among proposals intended to bypass inefficiency at the federal level, he announced the formation of an Oncology Center of Excellence at the U.S. Food and Drug Administration, which will coordinate and review all of FDA cancer treatments.
We are moving into a very complicated area in oncology where drugs and devices and biologics are going to be used in combination or sequentially.- Dr. Richard Pazdur
Biden also called out drug companies for unnecessary price increases and major research hospitals for insufficient collaboration.
"It's not anybody's fault, but we've got to fix it," Biden said.
Cancer researchers and their institutions have pushed back on those critiques, arguing they already share reams of data and partner frequently with each other and the government. They've also cited major hurdles imposed by federal agencies with intense bureaucratic requirements that make it near-impossible to develop treatments quickly and get them approved for patients — a concern that Biden acknowledged.
Under the existing review system, companies submit products to different divisions of the agency depending on whether it is a drug, device or biologic, a drug made from living cells. A treatment that combines a drug and a diagnostic device could get reviewed on different timelines.
Pazdur will oversee the establishment of the centre and act as its director for the next 120 days, with the potential for the position to be renewed. He will report directly to FDA Commissioner Robert Califf.
Biden outlined a slew of other collaborations and initiatives, including making it easier for patients to find and enter clinical trials through the creation of a cancer trials website and making it easier for scientists to focus on research and less on raising money.
With files from The Associated Press